Skip to main content

Table 4 Shift tables of laboratory values based on notable/extended ranges

From: Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study

 

Baseline

Worst post-baseline value

ALT (U/L)

n (%)

≤ ULN, n (%)

> ULN to ≤ 5 × ULN, n (%)

> 5 × ULN, n (%)

Notable range, n (%)

Extended range, n (%)

≤ ULN

34 (64.2)

19 (55.9)

14 (41.2)

0

0

1 (2.9)

> ULN to ≤ 5 × ULN

19 (35.8)

0

17 (89.5)

0

2 (10.5)

0

Total

53 (100.0)

19 (35.8)

31 (58.5)

0

2 (3.8)

1 (1 .9)

AST (U/L)

n (%)

≤ ULN, n (%)

> ULN to ≤ 5 × ULN, n (%)

> 5 × ULN, n (%)

Notable range, n (%)

Extended range, n (%)

≤ ULN

41 (77.4)

23 (56.1)

17 (41.5)

0

0

1 (2.4)

> ULN to ≤ 5 × ULN

12 (22.6)

0

12 (100.0)

0

0

0

Total

53 (100.0)

23 (43.4)

29 (54.7)

0

0

1 (1.9)

Serum creatinine

n (%)

≤ ULN, n (%)

Two consecutive > ULN, n (%)

Notable range, n (%)

Missing, n (%)

 

≤ ULN

53 (100.0)

51 (96.2)

2 (3.8)

0

0

 

Total

53 (100.0)

51 (96.2)

2 (3.8)

0

0

 

Creatinine clearance

n (%)

≥ 60, n (%)

One value ≥ 40 to < 60, n (%)

Notable range, n (%)

One value < 40, n (%)

Extended range, n (%)

≥ 60

50 (94.3)

45 (90.0)

2 (4.0)

1 (2.0)

2 (4.0)

0

≥ 40 to < 60

2 (3.8)

0

1 (50.0)

1 (50.0)

0

0

Missing

1 (1.9)

1 (100.0)

0

0

0

0

Total

53 (100.0)

46 (86.8)

3 (5.7)

2 (3.8)

2 (3.8)

0

Urinary protein/urinary creatinine ratio (mg/mmol)

n (%)

≤ 113.1, n (%)

One value > 113.1, n (%)

Two values > 113.1, n (%)

Notable range, n (%)

Missing, n (%)

≤ 113.1

48 (90.6)

39 (81.3)

5 (10.4)

3 (6.3)

1 (2.1)

0

> 113.1

1 (1.9)

1 (100.0)

0

0

0

0

Missing

4 (7.5)

3 (75.0)

0

0

0

1 (25.0)

Total

53 (100.0)

43 (81.1)

5 (9.4)

3 (5.7)

1 (1.9)

1 (1.9)

  1. ALT alanine aminotransferase, AST aspartate aminotransferase, ULN upper limit of normal